SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Horn N. R.) "

Sökning: WFRF:(Horn N. R.)

  • Resultat 241-250 av 256
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
241.
  • Gorski, Mathias, et al. (författare)
  • Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies
  • 2022
  • Ingår i: Kidney International. - : Elsevier. - 0085-2538 .- 1523-1755. ; 102:3, s. 624-639
  • Tidskriftsartikel (refereegranskat)abstract
    • Estimated glomerular filtration rate (eGFR) reflects kidney function. Progressive eGFR-decline can lead to kidney failure, necessitating dialysis or transplantation. Hundreds of loci from genome-wide association studies (GWAS) for eGFR help explain population cross section variability. Since the contribution of these or other loci to eGFR-decline remains largely unknown, we derived GWAS for annual eGFR-decline and meta-analyzed 62 longitudinal studies with eGFR assessed twice over time in all 343,339 individuals and in high-risk groups. We also explored different covariate adjustment. Twelve genomewide significant independent variants for eGFR-decline unadjusted or adjusted for eGFR- baseline (11 novel, one known for this phenotype), including nine variants robustly associated across models were identified. All loci for eGFR-decline were known for cross-sectional eGFR and thus distinguished a subgroup of eGFR loci. Seven of the nine variants showed variant- by-age interaction on eGFR cross section (further about 350,000 individuals), which linked genetic associations for eGFR-decline with agedependency of genetic cross- section associations. Clinically important were two to four-fold greater genetic effects on eGFR-decline in high-risk subgroups. Five variants associated also with chronic kidney disease progression mapped to genes with functional in- silico evidence (UMOD, SPATA7, GALNTL5, TPPP). An unfavorable versus favorable nine-variant genetic profile showed increased risk odds ratios of 1.35 for kidney failure (95% confidence intervals 1.03- 1.77) and 1.27 for acute kidney injury (95% confidence intervals 1.08-1.50) in over 2000 cases each, with matched controls). Thus, we provide a large data resource, genetic loci, and prioritized genes for kidney function decline, which help inform drug development pipelines revealing important insights into the age-dependency of kidney function genetics.
  •  
242.
  • Gorski, Mathias, et al. (författare)
  • Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
  • 2021
  • Ingår i: Kidney International. - : Elsevier. - 0085-2538 .- 1523-1755. ; 99:4, s. 926-939
  • Tidskriftsartikel (refereegranskat)abstract
    • Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m2/year or more ("Rapid3"; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25% or more and eGFRcrea under 60 mL/min/1.73m2 at follow-up among those with eGFRcrea 60 mL/min/1.73m2 or more at baseline ("CKDi25"; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or LARP4B. Individuals at high compared to those at low genetic risk (8-14 vs 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.
  •  
243.
  •  
244.
  • Jayaramulu, K., et al. (författare)
  • Covalent Graphene-MOF Hybrids for High-Performance Asymmetric Supercapacitors
  • 2021
  • Ingår i: Advanced Materials. - : Wiley-VCH Verlag. - 0935-9648 .- 1521-4095. ; 33:4
  • Tidskriftsartikel (refereegranskat)abstract
    • In this work, the covalent attachment of an amine functionalized metal-organic framework (UiO-66-NH2 = Zr6O4(OH)4(bdc-NH2)6; bdc-NH2 = 2-amino-1,4-benzenedicarboxylate) (UiO-Universitetet i Oslo) to the basal-plane of carboxylate functionalized graphene (graphene acid = GA) via amide bonds is reported. The resultant GA@UiO-66-NH2 hybrid displayed a large specific surface area, hierarchical pores and an interconnected conductive network. The electrochemical characterizations demonstrated that the hybrid GA@UiO-66-NH2 acts as an effective charge storing material with a capacitance of up to 651 F g−1, significantly higher than traditional graphene-based materials. The results suggest that the amide linkage plays a key role in the formation of a π-conjugated structure, which facilitates charge transfer and consequently offers good capacitance and cycling stability. Furthermore, to realize the practical feasibility, an asymmetric supercapacitor using a GA@UiO-66-NH2 positive electrode with Ti3C2TX MXene as the opposing electrode has been constructed. The cell is able to deliver a power density of up to 16 kW kg−1 and an energy density of up to 73 Wh kg−1, which are comparable to several commercial devices such as Pb-acid and Ni/MH batteries. Under an intermediate level of loading, the device retained 88% of its initial capacitance after 10 000 cycles. © 2020 The Authors. Advanced Materials published by Wiley-VCH GmbH
  •  
245.
  •  
246.
  • Norkin, Maxim, et al. (författare)
  • Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
  • 2019
  • Ingår i: Biology of blood and marrow transplantation. - : Elsevier BV. - 1083-8791 .- 1523-6536. ; 25:2, s. 362-368
  • Tidskriftsartikel (refereegranskat)abstract
    • We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for ≥2 years after first HCT without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of LFIs was 6.4% (95% confidence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in pediatric subjects; P < .001). In adults, the 2 most significant risks for developing LFI were increasing age (20 to 39, 40 to 54, and ≥55 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86 (95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD (cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR, 3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most significant risks for developing LFI were a history of cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI, 1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD.
  •  
247.
  •  
248.
  •  
249.
  •  
250.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 241-250 av 256
Typ av publikation
tidskriftsartikel (126)
konferensbidrag (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (246)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Li, H. (187)
Wang, J. (185)
Chen, H. (184)
Clark, A. (184)
Fox, H. (184)
Francis, D. (184)
visa fler...
Gorelov, I. (184)
March, L. (184)
Price, D. (184)
Robson, A. (184)
Snyder, S. (184)
Walker, R. (184)
Borissov, G. (183)
Boudreau, J. (183)
Brandt, A. (183)
Caughron, S. (183)
Chakraborty, D. (183)
Cooke, M. (183)
D'Onofrio, M. (183)
Davies, M. (183)
Esposito, B. (183)
Evans, H. (183)
Giokaris, N. (183)
Hohlfeld, M. (183)
Hou, S. (183)
Hubacek, Z. (183)
Hughes, G. (183)
Kehoe, R. (183)
Khanov, A. (183)
Kim, S. H. (183)
Kupco, A. (183)
LeCompte, T. (183)
Limosani, A. (183)
Lipeles, E. (183)
Liu, Y. (183)
Loginov, A. (183)
Lokajicek, M. (183)
Martinez, M. (183)
Mehta, A. (183)
Meyer, J. (183)
Nielsen, J. (183)
Nodulman, L. (183)
Pleier, M. -A. (183)
Quadt, A. (183)
Sawyer, L. (183)
Simak, V. (183)
Wilson, A. (183)
Zhang, H. (183)
Grinstein, S. (183)
Bernhard, R. (183)
visa färre...
Lärosäte
Uppsala universitet (57)
Lunds universitet (52)
Karolinska Institutet (51)
Kungliga Tekniska Högskolan (44)
Stockholms universitet (43)
Göteborgs universitet (12)
visa fler...
Högskolan Dalarna (6)
Umeå universitet (5)
Chalmers tekniska högskola (4)
Linköpings universitet (3)
Mittuniversitetet (2)
Linnéuniversitetet (2)
Örebro universitet (1)
visa färre...
Språk
Engelska (256)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (50)
Medicin och hälsovetenskap (32)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy